PATENT CLAIM ANALYSIS

Application Number: 15926716
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["424", "192100"]

Abstract:
Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.

Claim (Index 105):
A method, comprising:\n administering to a subject having a cancer a nucleic acid encoding a fusion protein, wherein the fusion protein comprises a cancer antigen fused to human macrophage inflammatory protein-3 alpha (MIP-3\u03b1); administering to the subject a CpG oligodeoxynucleotide; and administering to the subject a cytokine or a nucleic acid encoding a cytokine.

Metadata:
- Claim Count in Document: 284.0
- Percentile: 90.0
- Lexical Diversity: 1.60784
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13206471', '13823581', '12928044', '13373224', '15512820']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7401180268135892
- 35 USC 102 Novelty (BERT): 0.5695615732430755
- Combined Prediction Score: 0.7230623814565379
- Mean Citation Score: 322.40604399999995
- Max Citation Score: 493.97092
- Similarity Product: 364.7201772897983

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test